Return on Tangible Equity (Quarterly)

Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity

ImmunoPrecise Antibodies Ltd. (IPA) had Return on Tangible Equity of -133.43% for the most recently reported fiscal quarter, ending 2025-01-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-01-31

Income Statement Financials
Revenue	$4.33M
Net Income	$-15.14M
Cost of Goods Sold	$2.01M
Gross Profit	$2.32M
Operating Expenses	$6.56M
Operating Income	$-2.23M
Non-Operating Income/Expense	$-15.02M
Pre-Tax Income	$-17.26M
Normalized Pre-Tax Income	$-2.36M
Income after Taxes	$-15.14M
Income from Continuous Operations	$-15.14M
Consolidated Net Income/Loss	$-15.14M
Normalized Income after Taxes	$1.59M
EBIT	$-2.23M
EBITDA	$-1.33M
Weighted-Average Shares Outstanding (Basic)	32.85M
Weighted-Average Shares Outstanding (Diluted)	32.85M
Earnings per Share (EPS) (Basic)	$-0.46
Earnings per Share (EPS) (Diluted)	$-0.46
Balance Sheet Financials
Current Assets	$14.59M
Property, Plant, and Equipment	$10.70M
Long-Term Assets	$17.44M
Total Assets	$32.02M
Current Liabilities	$6.28M
Long-Term Debt	$7.90M
Long-Term Liabilities	$8.07M
Total Liabilities	$14.35M
Common Equity	$17.67M
Tangible Shareholders Equity	$11.34M
Shareholders Equity	$17.67M
Common Shares Outstanding	45.77M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-3.71M
Cash Flow from Investing Activities	$-0.31M
Cash Flow from Financial Activities	$10.77M
Beginning Cash	$2.49M
End Cash	$9.15M
Increase/Decrease in Cash	$6.65M
Stock-Based Compensation	$0.28M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.32
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.31
Debt to Equity Ratio	0.51
Gross Margin	53.57%
Operating Margin	-51.62%
EBIT Margin	-51.62%
EBITDA Margin	--
Pre-Tax Profit Margin	-398.88%
Profit Margin	-349.88%
Free Cash Flow	$-4.02M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.14
Inventory Turnover	1.49
Receiveable Turnover	1.63
Days Sales in Receivables	55.35
Return on Equity	-85.66%
Return on Tangible Equity	-133.43%
Return on Assets	-47.26%
Return on Investments	-59.18%
Book Value Per Share	$0.39
Free Cash Flow per Share	$-0.12
Operating Cash Flow per Share	$-0.11

Data from Zacks Investment Research, Inc.